Quantumzyme Expands AI Enzyme Platform to Transform Pharmaceutical Manufacturing

Quantumzyme Corp. has announced the expansion of its proprietary AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients beyond ibuprofen. This strategic initiative represents a significant advancement in green pharmaceutical manufacturing, with potential to substantially reduce hazardous waste, toxic solvent use, and carbon emissions at industrial scale.

The expanded program builds on the company's validated enzymatic process for green ibuprofen synthesis, leveraging Quantumzyme's enzyme families, machine learning predictive models, and in silico design workflows to develop sustainable pathways for other APIs with substantial global environmental impact. The company's enzyme engineering platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts that replace traditional energy-intensive chemical reaction steps.

The expanded research and development pipeline includes multiple high-volume APIs, including chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely used in the global generics sector. This expansion demonstrates the scalability of Quantumzyme's digital biology architecture and its capacity to rapidly adapt and redeploy enzyme systems across diverse synthesis targets.

The global API market is projected to exceed $300 billion by 2030, with generic drugs representing the majority of production volume. Much current manufacturing occurs overseas using legacy chemistries that generate heavy waste streams and carry high solvent and carbon intensity. Quantumzyme's biocatalysis-first approach offers a sustainable alternative that delivers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency.

Quantumzyme's platform also supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals. The company's vision to redefine chemical manufacturing through sustainable innovation involves extending the enzyme engineering platform beyond ibuprofen to advance greener chemistry and support supply chain resiliency. This expansion moves the industry closer to a future where enzyme-driven production becomes the standard for high-volume APIs. For additional information, visit https://www.quantumzymecorp.com and https://www.otcmarkets.com/stock/QTZM.